Nuclear imaging potential and in vitro photodynamic activity of symmetrical and asymmetrical zinc phthalocyanines. (5th April 2016)

• Record Type: Journal Article
• Authors: Yurt Lambrecht, Fatma; Ocakoglu, Kasim; Er, Ozge; Ince, Mine; Gunduz, Cumhur; Kayabası, Cagla
• Is Part Of: Journal of labelled compounds & radiopharmaceuticals. Volume 59:Number 5(2016)
• Page Start: 221
• Page End: 227
• Publication Date: 2016-04-05
• Subjects: photodynamic therapy -- symmetric phthalocyanine -- asymmetric phthalocyanine -- 131I -- breast cancer cell; Tracers (Chemistry) -- Periodicals; Radiopharmaceuticals -- Periodicals; 615.8424
• DOI: 10.1002/jlcr.3395
• Languages: English
• ISSNs: 0362-4803

Abstract

Abstract : Photodynamic therapy (PDT) is based on exposing a light‐sensitive material that has been localized in target tissues with visible light. In the current study, symmetric Zn(II) octaoctadodecylphthalocyanine (1) and the asymmetrically substituted hydroxyhexyloxy derivative (2) were examined as a multifunctional agent for tumour nuclear imaging and for PDT potential. Zn(II)Pc 1 and Zn(II)Pc 2 were radiolabelled with 131 I using an iodogen method with high efficiency (93.5 ± 3.5% and 93.0 ± 2.8%, respectively) under the optimum conditions. Biodistribution study results showed that radiolabelled Zn(II)Pc 1 had a high uptake in the large intestine and unchanging uptake in the ovary. However, radiolabelled Zn(II)Pc 2 uptake was statically significant in the large intestine, pancreas, ovary and lung. For the PDT studies, EMT6/P (mouse mammary cell line) and HeLa (cervical adenocarcinoma cell line) with Zn(II)Pc 1 and Zn(II)Pc 2 were exposed to red light (650 nm) at 10–30 J/cm 2 . Zn(II)Pc 1 and Zn(II)Pc 2 had a good PDT efficacy in the EMT6/P cell line. In conclusion, radiolabelled Zn(II)Pc 1 might be a promising imaging agent for pancreas, ovary and colon tumours. However, the radiolabelled Zn(II)Pc 2 might be a promising nuclear imaging and PDT agent for colon, lung, pancreas and ovary tumours. Abstract : In the photodynamic therapy studies, EMT6/P and HeLa cells with Zn(II)Pc 1 and Zn(II)Pc 2 were exposed to red light (650 nm) at 10–30 J/cm 2 . Zn(II)Pc 1 and Zn(II)Pc 2 had a good photodynamic therapy efficacy in the EMT6/P cell line. In conclusion, 131 I labelled Zn(II)Pc 1 and 131 I labelled Zn(II)Pc 2 might be a promising imaging agent for pancreas, ovary and colon tumours nuclear imaging.